Intranasal Leptin Prevents Opioid-induced Sleep-disordered Breathing in Obese Mice.
Ontology highlight
ABSTRACT: Respiratory depression is the main cause of morbidity and mortality associated with opioids. Obesity increases opioid-related mortality, which is mostly related to comorbid obstructive sleep apnea. Naloxone, a μ-opioid receptor blocker, is an effective antidote, but it reverses analgesia. Like humans with obesity, mice with diet-induced obesity hypoventilate during sleep and develop obstructive sleep apnea, which can be treated with intranasal leptin. We hypothesized that intranasal leptin reverses opioid-induced sleep-disordered breathing in obese mice without decreasing analgesia. To test this hypothesis, mice with diet-induced obesity were treated with morphine at 10 mg/kg subcutaneously and with leptin or placebo intranasally. Sleep and breathing were recorded by barometric plethysmogr
SUBMITTER: Freire C
PROVIDER: S-EPMC7528928 | biostudies-literature | 2020 Oct
REPOSITORIES: biostudies-literature
ACCESS DATA